Cudahy, California Clinical Trials

A listing of Cudahy, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

The primary objective of this study is to demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following administration of 2 doses of MenACYW conjugate vaccine compared to 2 doses of MENVEO when given concomitantly with routine pediatric vaccines to infants and toddlers 6 …

Investigational Site Number 8400073
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +47 other locations
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)  

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at …

University of Southern California, Los Angeles Site Number : 8400118
 (6.4 away)
  • 0 views
  • 04 Mar, 2025
  • +58 other locations
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled. The treating neurologist must make an …

USC Keck School Of Medicine
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +30 other locations
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

treatment regimen
lasmiditan
headache
preventive medication
migraine
Core Healthcare Group
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +162 other locations
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants  

Primary Objective: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection). To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups …

Investigational Site Number 8400030
 (2.4 away)
  • 0 views
  • 19 Feb, 2024
  • +31 other locations
None

University of Southern California
 (6.4 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
None

University of Southern California
 (6.4 away) Contact site
  • 0 views
  • 19 May, 2025
  • +12 other locations
None

University of Southern California
 (6.4 away) Contact site
  • 0 views
  • 19 May, 2025
  • +13 other locations
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a …

Core Healthcare Group- Site Number : 8400067
 (9.4 away) Contact site
  • 0 views
  • 29 Nov, 2025
  • +30 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

resting tremor
bradykinesia
modafinil
genetic testing
muscle rigidity
Keck School of Medicine of USC
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +45 other locations